Key Highlights

  • SkinJect's D-MNA patch, a doxorubicin-tipped microneedle array for nodular basal cell carcinoma, posted March 2026 topline Phase 2 results of 73% clinical clearance and 40% histological clearance in its 200-microgram cohort at Day 57, versus 38% clinical clearance for the device-only arm.
  • Medicus completed its acquisition of UK-based Antev Ltd. in August 2025, adding Teverelix, a GnRH antagonist for prostate cancer and acute urinary retention, which received FDA clearance in February 2026 to begin a Phase 2b dose-optimization study.
  • Cash fell to $6.37 million as of March 31, 2026, from $8.71 million three months earlier, against a $9.04 million quarterly net loss; filings disclose "substantial doubt" about its ability to continue as a going concern within one year.
  • Beyond the pending SKNJCT-003 study report, Medicus is pursuing an end-of-Phase-2 FDA meeting for the D-MNA program, has applied for an FDA Commissioner's National Priority Voucher, and is pursuing an Expanded Access IND with the Gorlin Syndrome Alliance for inoperable BCC patients.

Medicus Pharma Ltd. (NASDAQ:MDCX), an Alberta-incorporated, Pennsylvania-based clinical-stage biotech, is testing a dissolvable microneedle patch loaded with doxorubicin as a non-surgical basal cell carcinoma treatment. Preliminary topline data released in March 2026 from its Phase 2 SKNJCT-003 trial showed encouraging clearance rates in the highest-dose cohort, but shrinking cash, going-concern language and rapid share-count growth complicate the picture.

A Needle-Free Skin Cancer Alternative

Basal cell carcinoma, the most common skin cancer in the United States, is diagnosed in more than five million cases annually, per published research Medicus Pharma cites; standard treatment, surgical excision, can leave visible scarring. Medicus Pharma's wholly owned subsidiary, SkinJect, is developing an alternative: a patch of hundreds of dissolvable microneedles delivering doxorubicin, a chemotherapy agent, directly into the tumor without cutting the skin. That kept MDCX on small-cap biotech investors' radar as its lead study neared a data readout in early 2026, though the company remains years from a marketable product.

A License Becomes a Platform

Medicus Pharma is incorporated in Alberta, Canada, but files as a domestic issuer (10-Ks and 10-Qs rather than the 20-F used by foreign private issuers) with executive offices in West Conshohocken, Pennsylvania, and 16 full-time employees, per its most recent annual report.

SkinJect licensed its core microneedle-array intellectual property from the University of Pittsburgh and Carnegie Mellon University in 2016. A first-in-human dose-escalation study, SKNJCT-001, found the doxorubicin patch well tolerated with no dose-limiting toxicity, per the fiscal 2025 10-K, while a follow-on study, SKNJCT-002, was paused early after patch-application variability and never resumed.

In August 2025, Medicus acquired roughly 98.6% of Antev Limited, a UK clinical-stage biotech, for about $2.97 million in cash plus 1,603,164 Medicus shares, with up to $65 million in additional contingent consideration tied to future Teverelix milestones.

Medicus Pharma (MDCX) Banks on SKNJCT-003 Topline Data

SKNJCT-003, the closest-watched catalyst, is a randomized, double-blind, three-arm Phase 2 study comparing two doxorubicin dose levels (100 and 200 micrograms) against a device-only microneedle control in nodular BCC patients, expanded from an original 60-patient target to 90 after a positive March 2025 interim look, and completed enrollment across nine U.S. sites in December 2025, with UK sites added later.

On March 5 and 9, 2026, Medicus disclosed topline results: the 200-microgram arm achieved 73% clinical clearance and 40% histological clearance at Day 57, versus 38% clinical clearance for the device-only arm at the same dose, per the 10-Q. Medicus called the gap a "clear separation," and on March 30, 2026, the trial's principal investigator called the dataset "clinically meaningful" and "decision-grade."

These figures warrant caution: they are company-reported topline numbers from roughly 30 patients per arm, not peer-reviewed or FDA-adjudicated, and the fiscal 2025 10-K said the full clinical study report, including safety analysis, remained in progress. No p-values or other statistical-significance measures appear in the filings, and the investigator's endorsement comes from a paid trial site lead, not an independent body. Whether the data support an end-of-Phase-2 FDA meeting under the 505(b)(2) pathway remains unresolved.

A second, smaller study, SKNJCT-004, is running in the United Arab Emirates, targeting up to 36 patients; the first patient enrolled in October 2025.

Widening Losses as Costs Accelerate

For the quarter ended March 31, 2026, Medicus reported a net loss of $9.04 million, up from $5.10 million a year earlier, per its May 2026 10-Q. G&A expenses nearly doubled to $5.89 million on higher consulting fees, added headcount and compliance costs tied to the U.S. domestic-issuer transition and Antev deal. R&D spending rose 34.8% to $2.70 million on new Teverelix work, partly offset by lower SkinJect costs as SKNJCT-003 wound down. Net loss per share was $0.31, better than $0.42 a year earlier, reflecting a larger share count rather than a smaller loss.

Cash Burn and an ATM Lifeline

Medicus held $6.37 million in cash as of March 31, 2026, down from $8.71 million at December 31, 2025, after using $8.97 million in operating cash, per the 10-Q. Total shareholders' equity attributable to the company was just $1.33 million at quarter-end. The filing states plainly that "substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued."

The company also carries an $8 million Yorkville debenture from September 2025 at 8% interest, rising to 18% on default, maturing September 17, 2026. Medicus has funded operations through repeated share issuance: a $4.0 million Nasdaq IPO in November 2024; roughly $20 million combined from a Regulation A offering, a public offering and two 2025 warrant-inducement deals; and an at-the-market program upsized from $15.3 million to $50 million on April 23, 2026. As a subsequent event, it sold 14.67 million more ATM shares for about $5.2 million net after quarter-end. Shares outstanding climbed from 11.8 million at the end of 2024 to nearly 40.0 million by March 31, 2026, before those additional shares, while warrants for another 7.28 million shares, at a weighted-average exercise price of $2.70, remained outstanding at quarter-end.

Growth Path: A Trial and a Prostate Asset

Beyond the pending SKNJCT-003 study report, Medicus is pursuing an end-of-Phase-2 FDA meeting for the D-MNA program, has applied for an FDA Commissioner's National Priority Voucher, and is pursuing an Expanded Access IND with the Gorlin Syndrome Alliance for inoperable BCC patients. For Teverelix, the February 2026 FDA clearance to begin a Phase 2b dose-optimization study is the next milestone.

Risks Behind the Headline

The Yorkville debenture matures within twelve months, and management has said further financing may be needed to meet it. Reliance on the ATM program and warrant inducements has multiplied the share count several times over in eighteen months, and further raises look likely. SKNJCT-003's topline numbers are preliminary and have not undergone independent statistical review. Both Antev and SkinJect remain pre-revenue, so operations depend on external financing.

Outlook

The optimistic case rests on SKNJCT-003 producing an efficacy signal robust enough to interest the FDA in the 505(b)(2) pathway and, eventually, a licensing deal with a larger partner, the route management prefers. Teverelix adds an unrelated shot in a large prostate-cancer market. The cautious case rests on the going-concern, debt-maturity and dilution risks already noted, while the flagship trial's results remain preliminary. Between those poles, a base case has Medicus funding operations through equity issuance while it finishes the SKNJCT-003 study report and FDA discussions.

Conclusion

Medicus Pharma Ltd. (MDCX) has produced an early, encouraging efficacy signal for its SkinJect microneedle patch in basal cell carcinoma and broadened its pipeline with the Antev prostate-cancer acquisition. But the same filings that disclose that data also disclose the going-concern, debt-maturity and dilution risks detailed above. For MDCX, the science and balance sheet are advancing on parallel, and not entirely aligned, tracks.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.